Nutrition 21
This article was originally published in The Tan Sheet
Executive Summary
Obtains exclusive patent rights for use of chromium to relieve symptoms of depression and premenstrual syndrome (U.S. Patent Nos. 6,034,125 and 5,972,390, respectively) when administered at doses ranging from 200 mcg to 500 mcg, Chromax manufacturer announces May 24. Ingredient supplier also is sponsoring upcoming study at Duke University Medical Center, led by Professor of Psychiatry Jonathan Davidson, MD, to further substantiate chromium picolinate's beneficial effects on depression
Obtains exclusive patent rights for use of chromium to relieve symptoms of depression and premenstrual syndrome (U.S. Patent Nos. 6,034,125 and 5,972,390, respectively) when administered at doses ranging from 200 mcg to 500 mcg, Chromax manufacturer announces May 24. Ingredient supplier also is sponsoring upcoming study at Duke University Medical Center, led by Professor of Psychiatry Jonathan Davidson, MD, to further substantiate chromium picolinate's beneficial effects on depression. |